rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid: A new option as immuno-therapy for osteosarcoma?

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 2559-2565

  Liebau, Christian ^a   Merk, Harry ^a   Roesel, Christian ^b   Schmidt, Sebastian ^a   Karreman, Christiaan ^b   Prisack, Johannes Bernd ^b   Bojar, Hans ^b   Baltzer, Axel W A ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b NONE

Author keywords

Gene therapy; IL 12; IL 18; Immunotherapy; Sarcoma

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; PLASMID VECTOR; RECOMBINANT INTERLEUKIN 18;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; IMMUNE SYSTEM; MONONUCLEAR CELL; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RAT; SURVIVAL RATE;

ANIMALS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DRUG SYNERGISM; GENE THERAPY; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-18; LEUKOCYTES, MONONUCLEAR; OSTEOSARCOMA; PLASMIDS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; TRANSDUCTION, GENETIC; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 0036765411     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Atkins MB, Robertson MJ, Gordon M, Lotze MT, De-Coste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H and Sherman ML: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3: 409-417, 1997.
2. Baltzer AWA, Whalen JD, Stefanovic-Racic M, Ziran B, Robbins PD and Evans CH: Adenoviral transduction of human osteoblastic cell cultures: A new perspective for gene therapy of bone diseases. Acta Orthop Scand 70: 419-424, 1999.
3. Baltzer AWA, Lattermann C, Whalen JD, Wooley P, Weiss K, Grimm M, Ghivizzani SC, Robbins PD and Evans CH: Genetic enhancement of fracture repair: Healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther 7: 734-739, 2000.
4. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G and Gately MK: Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol 17: 71-77, 1995.
5. Brunda MJ, Luistro L, Rumennik L, Wright RB, Wigginton JM, Wiltrout RH, Hendrzak JA and Palleroni AV: Interleukin-12: murine models of a potent antitumor agent. Ann N Y Acad Sci 31: 266-74, 1996.
6. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, Young HA, Wolf SF, Young D, Clark SC and Trinchieri G: Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 173: 869-79, 1991.
7. Cohen J: IL-12 deaths: explanation and a puzzle. Science 270: 908, 1995.
8. Fukumoto H, Nishio M, Nishio K, Heike Y, Arioka H, Kurokawa HT, Fukuoka K, Nomoto T, Ohe Y and Saijo N: Interferon-gamma-inducing factor gene transfection into Lewis rat lung carcinoma cells reduces tumorigenicity in vivo. Jpn J Cancer Res 88: 501-505, 1997.
9. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U and Presky DH: The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 16: 495-521, 1998.
10. Gubler U, Chua AO, Schoenhaut DS, Dwyer CM, McComas W, Motyka R, Nabavi N, Wolitzky AG, Quinn PM, Familletti PC and Gately MK: Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 88: 4143-4147, 1991.
11. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ and Lotze MT: Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153: 1697-1706, 1994.
12. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y and Hattori K: Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88-91, 1995.
13. Osaki T, Peron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT and Tahara HL: IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma and IL-12-independent antitumor effects. J Immunol 160: 1742-1749, 1998.
14. Osaki T, Hashimoto W, Gambotto A, Okamura H, Robbins PD, Kurimoto M, Lotze MT and Tahara H: Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther 6: 808-815, 1999.
15. Rakhmilevich AL, Turner J, Ford MJ, McCabe D, Sun WH, Sondel PM, Grota K and Yang NS: Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 93: 6291-6296, 1996.
16. Tahara H, Zeh HJ 3rd, Storkus WJ, Pappo I, Watkins SC, Gubler U, Wolf SF, Robbins PD and Lotze MT: Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54: 182-189, 1994.
17. Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT and Tahara H: Rapid generation of potent and tumor-specific cytotoxic T-lymphocytes by interleukin 18 using dentritic cells and natural killer cells. Cancer Res 60: 4838-4844, 2000.
18. Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, Tanabe F, Konishi K, Micallef M, Fujii M, Torigoe K, Tanimoto T, Fukuda S, Ikeda M, Okamura H and Kurimoto M: Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 156: 4274-4279, 1996.
19. Wolf SF, Temple PA, Kobayashi M, Young E, Dicig M, Lowe L, Dzialo R, Fitz L, Ferenz C, Hewick RM, Kelleher K, Herrmann SH, Clark SC, Azzoni L, Chan SH, Trinchieri G and Perussia B: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146: 3074-3081, 1991.
20. Worth LL, Jia SF, Zhou Z, Chen L and Kleinerman ES: Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin Cancer Res 6: 3713-3718, 2000.
21. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA and Lotze MT: Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 155: 1393-1403, 1995.